 CAMBRIDGE, Mass. , June 23, 2022 PRNewswire -- Omega Therapeutics, Inc. Nasdaq: OMGA Omega, a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines by leveraging its OMEGA Epigenomic ProgramingTM platform, today announced that it will present preclinical data for OTX-2002, the Companys lead candidate for the treatment of hepatocellular carcinoma HCC, at the upcoming European Society of Medical Oncology ESMO 2022 World Congress on Gastrointestinal GI Cancer, taking place in Barcelona, Spain, June 29 - July 2, 2022. 